



**CONTACT:** Candace Shaw, Contour Media LLC

**EMAIL:** [candacesshaw@contourmediallc.com](mailto:candacesshaw@contourmediallc.com)

**PHONE:** 219-276-0928

### **FOR IMMEDIATE RELEASE**

#### **IVDiagnostics and Prevail Partners, LLC announce strategic partnership**

**Gary, IN 10/23/2017** - IVDiagnostics and Prevail Partners, Inc. are excited to announce a strategic partnership that will efficiently and economically drive the Phase 1 FDA approval process for IVDiagnostics revolutionary breast cancer assay technology, Velox™. The Velox™ diagnostic cancer test tags and monitors circulating tumor cells in a cancer patient's body allowing Doctors and Oncologists to provide more accurate and frequent monitoring of a patient's progress during and after treatment.

Prevail InfoWorks, Inc., a subsidiary company of Prevail Partners, will provide IVDiagnostics with considerable value by cost effectively achieving the highest quality data in the shortest possible time during IVDiagnostics clinical studies. Prevail Partners, the capital arm of Prevail InfoWorks, Inc will also invest in IVDiagnostics per terms of their agreement.

Mary Schaheen, President of Prevail Partners stated that "Everyone at Prevail Partners is excited to invest in the growth of IVDiagnostics as they develop the fastest and lowest cost CTC assay for the accurate in-vitro monitoring of pathogenic cell growth in patients undergoing cancer treatment or other blood borne diseases. Furthermore, we have great confidence in our partnership and its ability to accelerate IVDiagnostics to a significant value inflection point through the completion of its planned pilot and pivotal trials."

Frank Szczepanski, President & CEO of IVDiagnostics expressed that “this partnership with the leading FDA approved analytics driven process and data management company is precisely what we need to succeed with the FDA approval of our initial breast cancer assay.”

IVDiagnostics is a national leader in the biotech industry and was the 2011-2012 Chanute Prize for Team Innovation recipient presented by the Society of Innovators and sponsored by Krieg DeVault Law Firm. IVDiagnostics received this award for their innovative research and development in cancer research. The Company has also received an eDay award from Small Business Development Center Region 5 being designated the 2011 Revolutionary Technology Company of the Year.

For further information or to connect with IVDiagnostics, email Frank Szczepanski, CEO at [frank@ivdiagnostics.com](mailto:frank@ivdiagnostics.com) or visit [www.ivdiagnostics.com](http://www.ivdiagnostics.com)

### **About IVDiagnostics**

Founded in October 2010, IVdiagnostics is a private biotech company located in Northwest Indiana on the Ivy Tech Gary campus. IVDiagnostics was formed to develop, test and market more effective diagnostic tools for addressing rare circulating tumor cells and blood borne diseases. By collaborating with several academic and commercial partners, the company has accelerated its research and development. The Company focuses on the development of precision cancer assays like Velox™, for diagnostic use by oncologists and pathologists who serve metastatic cancer patients.

### **About Velox™**

Is a Cancer Assay test that tags and monitors circulating tumor cells (CTC) in the body. The Velox™ test can capture individual cancer cells that are within 2-30 microns in size. The problem with relying on current imaging systems is that they can only detect solid tumors of 1mm or greater in size. Ideally Velox™ is used for patients with metastatic (advanced stage) cancers.

### **About Prevail Partners, LLC**

Prevail Partners is an investment fund focused on life sciences companies. The fund is designed to take advantage of, at very favorable terms, the attractive returns possible in promising scientific advances in the fields of healthcare therapies, preventive treatments, medical devices and diagnostics. A uniquely favorable feature of the fund is that Prevail InfoWorks applies proprietary technologies to

equip companies in which the fund invests, giving investors comfort that the trials have a high likelihood of success.

**About Prevail InfoWorks**

For over a decade, Prevail InfoWorks has been dedicated to providing biotech, pharmaceutical, and medical device enterprises with the most innovative and complete technology solutions. The company delivers unique products and series that accelerate and de-risk drug development and clinical regulatory process more rapidly and cost effectively. Prevail InfoWorks is a subsidiary company of Prevail Partners, LLC